Purpose
Prognostic metrics for the rapid and accurate prediction of sepsis severity that could elicit a meaningful change in clinical practice are currently lacking. Here, we evaluated a whole blood, multiplex host mRNA expression metric, Inflammatix-Severity-2 (IMX-SEV-2), for identifying septic, hospitalized patients for 30-day mortality, development of chronic critical illness (CCI), discharge disposition, and/or secondary infections.
Methods This is a retrospective, validation cohort analysis of a prospectively enrolled 335 patient study with surgical sepsis treated in the surgical intensive care unit. Whole blood collected in PAXgene® Blood RNA collection tubes at 24 hours post sepsis diagnosis was analyzed using a custom 29-mRNA classifier (IMX-SEV-2) in a CLIA-CAP-accredited diagnostic laboratory using the NanoString FLEX® profiler.
Results Among patients meeting Sepsis-3 criteria, the IMX-SEV-2 severity score was significantly better (p<0.05) at predicting secondary infections (AUROC 0.71) and adverse clinical outcomes (AUROC 0.75) than C-reactive protein (CRP), absolute lymphocyte counts (ALC), total white blood cell (WBC) count, age and Charlson comorbidity index (and better, albeit nonsignificantly, than IL-6 and APACHE II). Using multivariate logistic regression analysis, only combining the Charlson comorbidity index (AUROC 0.80) or APACHE II (AUROC 0.81) with the IMX-SEV-2 significantly improved prediction of adverse clinical outcomes, and combining with the Charlson comorbidity index for predicting 30-day mortality (AUROC 0.79).
Conclusions The IMX-SEV-2 severity score was superior at predicting secondary infections and overall adverse clinical outcomes versus other common metrics. Importantly, combining a rapidly measured transcriptomic metric with clinical or physiologic indices has sufficient precision to optimize resource utilization and allow adjustments to patient management that may improve outcomes in surgical sepsis. Hospitalized patients who are septic and present with an elevated IMX-SEV2 severity score and pre-existing comorbidities would be strong candidates for clinical interventions aimed at reducing the risk of secondary infections and adverse clinical outcomes.
Competing Interest Statement
Conflicts of Interest and Source of Funding: This project has been funded in part with U.S. Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), DRIVe program, under Contract 75A50119C00044. The original observational clinical study was funded under P50 GM-111152, awarded by the National Institute of General Medical Sciences (NIGMS). DD and BF were funded by a post-graduate training grant in burns, trauma, sepsis and perioperative injury from the NIGMS (T32 GM-008721). UM, JW, PL, OL and TE are employees of Inflammatix, Inc. (Burlingame, CA, USA). SB, PS, and LLM received research support for aspects of this study under BARDA subcontract. The remaining authors have disclosed that they do not have any conflicts of interest.
Clinical Trial
NCT02276417
Funding Statement
This project has been funded in part with U.S. Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), DRIVe program, under Contract 75A50119C00044. The original observational clinical study was funded under P50 GM-111152, awarded by the National Institute of General Medical Sciences (NIGMS). DD and BF were funded by a post-graduate training grant in burns, trauma, sepsis and perioperative injury from the NIGMS (T32 GM-008721).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained from the University of Florida Institutional Review Board (#201400611).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of Interest and Source of Funding: This project has been funded in part with U.S. Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), DRIVe program, under Contract 75A50119C00044. The original observational clinical study was funded under P50 GM-111152, awarded by the National Institute of General Medical Sciences (NIGMS). DD and BF were funded by a post-graduate training grant in burns, trauma, sepsis and perioperative injury from the NIGMS (T32 GM-008721). UM, JW, PL, OL and TE are employees of Inflammatix, Inc. (Burlingame, CA, USA). SB, PS, and LLM received research support for aspects of this study under BARDA subcontract. The remaining authors have disclosed that they do not have any conflicts of interest.
The entire clinical data set used in the preparation of this report is freely accessible through the website, https://www.ctsi.ufl.edu/research/laboratory-services/ctsi-biorepository-2/scirc-specimens-archive/ under management of the University of Florida Clinical and Translational Science Institute Biorepository.
Data Availability
The data from this study is available upon contact of the primary investigators and Inflammatix, Inc.
